PARP1 Inhibition by Olaparib Reduces the Lethality of Pancreatic Cancer Cells and Increases Their Sensitivity to Gemcitabine

Viability, radiosensitization, angiogenesis, migration, colony formation, TUNEL, cell cycle, multicellular tumorsphere induction, and in vivo assays were performed to test the influence of PARP1 inhibition on resistance phenomena and tumor progression.